Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

PHASE3CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Depressive Disorder, Major
Interventions
DRUG

vilazodone

titration to 40mg tablets qd for 8 weeks

Trial Locations (15)

11235

Social Psychiatry Research Institute, Brooklyn

29407

Southeast Health Consultants, LLC, Charleston

30060

Atlanta Institute of Medicine & Research, Marietta

30328

Atlanta Institute of Medicine & Research, Atlanta

48336

Summit Research Network (Michigan), Inc., Farmington Hills

48507

Summit Research Network (Michigan), Inc., Flint

84132

University of Utah health Services Center Dept. of Psychiatry Mood and Anxiety Disorders, Salt Lake City

90720

Pharmacology Research Institute, Los Alamitos

91324

Pharmacology Research Institute, Northridge

92506

Pharmacology Research Institute, Riverside

92660

Pharmacology Research Institute, Newport Beach

97210

Summit Research Network (Oregon) Inc., Portland

98004

Northwest Clinical Research Center, Bellevue

98104

Summit Research Network (Seattle) LLC, Seattle

19104-3309

University of Pennsylvania Department of Psychiatry Mood and Anxiety Disorders Section, Philadelphia

Sponsors
All Listed Sponsors
lead

Genaissance Pharmaceuticals

INDUSTRY